证券代码：600624 证券简称：复旦复华 编号：临 2025-037 上海复旦复华科技股份有限公司 第十一届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案须经 2025 年第二次临时股东大会审议通过。 特此公告。 上海复旦复华科技股份有限公司监事会 2025 年 8 月 7 日 关于取消监事会暨修改《公司章程》的议案 详见公司公告临 2025-038《上海复旦复华科技股份有限公司关于取消监事 会暨修改<公司章程>的公告》。 同意 6 票，弃权 0 票，反对 0 票 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 8 月 6 日以 通讯方式召开公司第十一届监事会第十一次会议，本次会议的通知和资料已于 2025 年 7 月 28 日发送给全体监事。公司监事会成员 6 名，实际参与表决 6 名， 本次会议的召开符合《公司法》和《公司章程》的有关规定。会议审议通过了如 下事项： ...

证券代码：600624 证券简称：复旦复华 公告编号：2025-036 上海复旦复华科技股份有限公司 第十一届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 8 月 6 日以 通讯方式召开公司第十一届董事会第十四次会议，本次会议的通知和资料已于 2025 年 7 月 28 日发送给全体董事。公司董事会成员 7 名，实际参与表决 7 名， 本次会议的召开符合《公司法》和《公司章程》的有关规定。会议审议通过了如 下事项： 1. 关于取消监事会暨修改《公司章程》的议案 详见公司公告临 2025-038《上海复旦复华科技股份有限公司关于取消监事 会暨修改<公司章程>的公告》。 详见公司公告临 2025-039《上海复旦复华科技股份有限公司关于修改部分 公司制度的公告》。 同意 7 票，弃权 0 票，反对 0 票 本议案须经股东大会审议通过。 3. 关于召开 2025 年第二次临时股东大会的议案 详见公司公告临 2025-040《上海复旦复华科 ...

Group 1: Regulatory Developments - The China Securities Regulatory Commission (CSRC) has approved the registration of monthly average futures for linear low-density polyethylene, polyvinyl chloride, and polypropylene at the Dalian Commodity Exchange [1] - The Guangzhou Futures Exchange is actively promoting the research and listing of platinum, palladium, and lithium hydroxide futures, expected to launch this year [1] Group 2: Market Trends - The number of ETFs with over 10 billion yuan in assets has surpassed 90, with the total ETF scale exceeding 4.6 trillion yuan, driven by thematic products in technology, dividends, and innovative pharmaceuticals [1] - Bond funds are facing significant redemption pressure, with over 200 billion yuan in bond sales in the first four days of the week, including nearly 100 billion yuan in a single day [2] Group 3: Insurance Sector - The preset interest rate for traditional life insurance products has been lowered by 50 basis points to 2.0%, while the guaranteed interest rate cap for participating insurance has been reduced to 1.75% [3] Group 4: Company Performance - IMAX China reported a record 25 million moviegoers in the first half of 2025, generating approximately 416 million yuan in revenue, doubling the box office compared to the same period last year [4] - LVMH's net profit for the first half of 2025 fell by 22% to 5.7 billion euros, with a significant decline in sales in Japan due to currency appreciation [4] - Vanke has successfully sold the Shanghai Jinqiao Wanchuang Center project, with market speculation suggesting a transaction price of around 1.4 billion yuan [5] - China Communications Construction Company signed new contracts worth 991.05 billion yuan in the first half of the year, a year-on-year increase of 3.14% [5] - Fudan Fuhua terminated the transfer of a 28% stake in a subsidiary due to a lack of interested buyers [6] - Feima International received 437 million yuan in performance compensation from its controlling shareholder [7] - Shanghai Construction Group reported a net profit of 710 million yuan in the first half of the year, a decrease of 14.04% [8] - Funi Co., Ltd. achieved a net profit of 1.337 billion yuan in the first half of the year, an increase of 12.48% [10] - Western Mining reported a net profit of 1.869 billion yuan in the first half of the year, a growth of 15% [11] - Bomaike's net profit dropped by 80.42% to 12.39 million yuan in the first half of the year [12]

Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

三、对公司的影响 本次终止事项不会影响公司的正常运营，不会对公司的财务状况和经营成果 产生重大影响，不会导致公司合并报表范围发生变更。 一、公开挂牌转让参股公司股权事项概况及进展情况 2023 年 12 月 7 日，上海复旦复华科技股份有限公司（以下简称"公司"） 第十一届董事会第一次会议、第十一届监事会第一次会议分别审议并通过了《关 于公开挂牌转让参股公司股权的议案》，同意公司通过上海联合产权交易所公开 挂牌转让公司所持复华龙章健康科技（上海）有限公司（以下简称"复华龙章" 或"标的公司"）28%的股权（详见公司公告临 2023-062《上海复旦复华科技股 份有限公司关于公开挂牌转让参股公司股权的公告》）。 二、公司终止公开挂牌转让参股公司股权的原因 公司近期收到上海联合产权交易所有限公司出具的《产权交易终结决定通 知》，鉴于公开挂牌期间意向受让方未交纳保证金，根据相关规定，上海联合产 权交易所有限公司决定终结复华龙章健康科技（上海）有限公司 28%股权项目。 因上述因素，公司终止该公开挂牌转让参股公司股权事项。 证券代码：600624 证券简称：复旦复华 编号：临 2025-034 上海复旦复华科技股份有 ...

上海复旦复华科技股份有限公司（以下简称"公司"）全资子公司上海复华 贤睿企业管理有限公司根据公司经营发展需要，对相关信息进行了工商变更。近 日，公司收到了上海市奉贤区市场监督管理局核发的新的《营业执照》，具体内 容公告如下： 变更前： 法定代表人：沈波 变更后： 法定代表人：李骁 证券代码：600624 证券简称：复旦复华 编号：临 2025-035 上海复旦复华科技股份有限公司 关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复华贤睿企业管理有限公司变更后的《营业执照》信息如下： 1 特此公告。 法定代表人：李骁 经营范围：一般项目：企业管理；企业管理咨询；信息咨询服务(不含许可 类信息咨询服务)；社会经济咨询服务；技术服务、技术开发、技术咨询、技术 交流、技术转让、技术推广；市场营销策划；企业形象策划；品牌管理；咨询策 划服务；第一类医疗器械销售(除依法须经批准的项目外，凭营业执照依法自主 开展经营活动)。 注册资本：人民币 3,000 万元整 成立日期：2021 年 11 月 1 ...

Group 1 - The company, Fudan Zhanghua (600624), has received a termination notice from Shanghai United Assets and Equity Exchange regarding the equity transfer project of 28% stake in Fuhua Longzhang Health Technology (Shanghai) Co., Ltd. [1] - The termination is due to the lack of deposit payment from potential buyers during the public listing period, leading to the decision to end the equity transfer process. [1]

证券代码：600624 证券简称：复旦复华 编号：临 2025-033 上海复旦复华科技股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1.上海复旦复华科技股份有限公司（以下简称"公司"）本期业绩预告适用 于净利润为负值。 2.公司预计 2025 年半年度实现归属于上市公司股东的净利润为-1,050 万元 到-700 万元，与上年同期相比实现减亏。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （一）公司 2024 年半年度利润总额：-1,692.87 万元。归属于上市公司股 东的净利润：-1,576.26 万元。归属于上市公司股东的扣除非经常性损益的净利 润：-2,085.56 万元。 （二）每股收益：-0.023 元。 1 三、本期业绩预亏的主要原因 2025 年上半年公司生产经营正常，经财务部门初步测算，预计 2025 年上半 年归属于上市公司股东的净利润为负值，具体原因如下： 公司控股子公司江苏复旦复 ...

证券代码：600624 证券简称：复旦复华 编号：临 2025-032 上海复旦复华科技股份有限公司 关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 类型：其他有限责任公司 法定代表人：董如芳 经营范围：一般项目：健康咨询服务（不含诊疗服务）；食品销售（仅销售 预包装食品）；远程健康管理服务；技术服务、技术开发、技术咨询、技术交流、 技术转让、技术推广；信息咨询服务（不含许可类信息咨询服务）；企业管理咨 询；财务咨询；会议及展览服务；市场营销策划；企业形象策划；日用百货销售； 第一类医疗器械销售；互联网销售（除销售需要许可的商品）。（除依法须经批准 的项目外，凭营业执照依法自主开展经营活动） 上海复旦复华科技股份有限公司（以下简称"公司"）全资子公司上海复华 辉耀大健康管理有限公司根据公司经营发展需要，对相关信息进行了工商变更。 近日，公司收到了上海市奉贤区市场监督管理局核发的新的《营业执照》，具体 内容公告如下： 变更前： 法定代表人：汤秋晨 变更后： 法定代表人：董如芳 上海复华辉耀大 ...

本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 27 日 证券代码：600624 证券简称：复旦复华 公告编号：2025-031 上海复旦复华科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 审议结果：通过 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长宋正先生主持。本次会议以现 场和网络投票相结合的方式对股东大会通知中列明的事项进行了投票表决，表决 方式符合《公司法》及《公司章程》的规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 (二)股东大会召开的地点：上海市奉贤区茂园路 50 号 37 号楼 16 楼第一会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 421 | | --- | --- | | 2、出席会议的股东所持有表决权的 ...